Pricing Log in Create free account

Mineralys Therapeutics, Inc. (MLYS) vs Urogen Pharma (URGN)

Mineralys Therapeutics, Inc. and Urogen Pharma are both Biotechnology companies. Mineralys Therapeutics, Inc. and Urogen Pharma are of similar size ($1.9B and $1.8B). Mineralys Therapeutics, Inc. has the higher net margin (0.00% vs −51.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Mineralys Therapeutics, Inc. leads on 6 and Urogen Pharma on 5.

Valuation

Metric MLYS URGN Biotechnology median
P/E n/m n/m 8.50
P/S n/m 9.23 9.71
P/B 3.12 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 9.66 9.21
Earnings yield (20.89%) (5.73%) (33.15%)
Free cash flow yield (8.07%) (9.14%) (25.50%)

Profitability

Metric MLYS URGN Biotechnology median
Gross margin — 90.85% 65.16%
Operating margin 0.00% (35.32%) 0.00%
Net margin 0.00% (51.73%) 0.00%
Free cash flow margin 0.00% (84.32%) 0.00%
Return on equity (80.88%) 86.49% (56.36%)
Return on assets (69.67%) (42.33%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MLYS URGN Biotechnology median
Revenue growth (TTM) — 100.27% 6.02%
EPS growth (last fiscal year) 37.43% (7.77%) 30.26%
Revenue growth, 5-year CAGR — 56.22% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MLYS URGN Biotechnology median
Debt to equity 0.18 (1.45) 0.00
Current ratio 34.46 3.80 4.72
Net debt to EBITDA 3.85 0.00 0.96

Dividend

Metric MLYS URGN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MLYS URGN Biotechnology median
Market cap 1.91b 1.79b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack